Company profile: Molecular Insight
1.1 - Company Overview
Company description
- Provider of biopharmaceutical innovations in molecular medicine, applying molecular-level disease identification and targeting to improve patient healthcare and address significant unmet medical needs.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Molecular Insight
Onxeo
HQ: France
Website
- Description: Provider of oncology drug R&D and platforms, offering Beleodaq (belinostat), a histone deacetylase inhibitor marketed in the US for injection; Livatag, a nanoparticle doxorubicin in Phase III for primary liver cancer; and pipeline programs including platON, a decoy oligonucleotide platform for cancer and inflammatory diseases; AsiDNA, a DNA-repair decoy; and VIO-01, a pan‑DDR decoy activating STING.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onxeo company profile →
OctreoPharm Sciences
HQ: Germany
Website
- Description: Provider of radiopharmaceuticals and theranostic solutions for neuroendocrine tumors, including OPS201, a peptide for PRRT with 90Yttrium or 177Lutetium, and OPS202, a 68Gallium-labeled PET imaging agent targeting somatostatin receptors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OctreoPharm Sciences company profile →
Shoreline Biosciences
HQ: United States
Website
- Description: Provider of engineered cellular immunotherapies for seriously ill patients, leveraging an iPSC-based modular development system for gene editing to optimize therapeutic profiles. Offerings include iNK cells to target and eliminate cancer cells and iMACs to modify the tumor microenvironment and stimulate an anti-tumor immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shoreline Biosciences company profile →
Koelis
HQ: France
Website
- Description: Provider of medical imaging solutions for urologists, including KOELIS Trinity MRI/US prostate biopsy system for accurate needle guidance in prostate cancer diagnosis and treatment; OBT Fusion for prostate tracking and core location recording with precise targeting; 3D Ultrasound with motion compensation; 2nd Look Option; and transperineal and transrectal tools with 3D probes, holders, guides, and accessories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Koelis company profile →
MiNK Therapeutics
HQ: United States
Website
- Description: Provider of allogeneic invariant natural killer T (iNKT) cell therapies and immune technologies, including AGENT-797 for solid tumors and severe ARDS; native iNKT therapies; engineered iNKT therapies with CARs and bispecific engagers; and platforms (CARDIS and IgG-based bispecific iNKT cell engagers) for discovering, optimizing, and developing targeted cancer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MiNK Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Molecular Insight
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Molecular Insight
2.2 - Growth funds investing in similar companies to Molecular Insight
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Molecular Insight
4.2 - Public trading comparable groups for Molecular Insight
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →